Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is ref

Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings

Wall Street analysts upgraded Parsons Corp, InnovAge Holding Corp, Equifax Inc, and initiated covera

Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO

Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safu

Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safu

The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock.

JP Morgan analyst Priyanka Grover initiates coverage on Nuvation Bio (NYSE:NUVB) with a Overweigh

Nuvation Bio (NYSE: NUVB - Get Free Report) and Pathfinder Cell Therapy (OTCMKTS:PFND - Get Free Rep

Nuvation Bio NYSE: NUVB reported second-quarter total revenue of $31.7 million, including $23.2 mill

RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and rais

Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript

Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.15 per share in line with the Zacks Co

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product

Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.18) per share which beat the analyst conse

Presentations Overview:WCLCTitle: Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Smal

Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key pati

Medical sector earnings are off to a strong start, and four biotech companies are positioned to pote

Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings

The consensus price target hints at a 94.3% upside potential for Nuvation Bio (NUVB). While empirica

HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and ra

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main

NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global on

Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest t

Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its

U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings exp

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progressi

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progressi

RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowe

Truist Securities analyst Gregory Renza maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises

NEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global onc

According to a Form 4 filing, a Nuvation Bio executive reported selling 125,000 Class A shares for a

FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PR

NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company f

U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release a

Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tacklin

NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global on

Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest ch

RBC Capital analyst Leonid Timashev reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and mai

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main

HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and m

Nuvation Bio (NYSE:NUVB) reported quarterly earnings of $0.01 per share which met the analyst consen

Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest ch

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest c

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global le

Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive